Exagen(US:XGN)2026-03-10 13:30Financial Data and Key Metrics Changes - In 2025, Exagen achieved record revenue of $66.6 million, a nearly 20% increase over 2024, driven by over 11% growth in testing volume and over 7% increase in trailing 12-month ASP [21][24] - The gross margin for 2025 was just over 58%, down from about 60% in 2024, reflecting ASP pressure in the second half of the year [23][24] - Operating expenses for 2025 were $53 million, up about 13% compared to 2024, indicating early signs of scale in the business as revenue growth outpaced expense growth [24][25] Business Line Data and Key Metrics Changes - The volume run rate increased from approximately 30,000 tests in Q1 2025 to over 35,000 tests in subsequent quarters, marking the highest Q4 testing volume in Exagen's history [12][21] - The ASP at the end of 2025 was approximately $441, up from $411 at the start of the year, reflecting successful execution in revenue cycle management and product enhancements [13][21] Market Data and Key Metrics Changes - The Pharma Services segment generated $1.7 million in revenue in 2025, significantly up from roughly $100,000 in 2024, with a backlog value of over $4 million expected to grow [23] - The company anticipates revenue for 2026 to be between $70 million and $73 million, with both volume and ASP growth contributing [19][27] Company Strategy and Development Direction - Exagen aims to own the entire autoimmune diagnostics space, focusing on comprehensive care and innovative solutions to address significant unmet needs in autoimmune disease diagnosis [6][19] - The company is prioritizing three objectives: advancing adoption through an upgraded sales force, expanding ASP through revenue cycle optimizations, and driving innovation with a structured product development cadence [20][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term opportunity for ASP growth, driven by strategic initiatives that have improved ASP from $280 to $441 over the past three years [27][28] - The company is focused on achieving positive adjusted EBITDA and sustainable cash flow, with a breakeven revenue run rate now expected to be around $80 million [28][30] Other Important Information - Exagen has launched three sets of innovative markers into the clinic within an 18-month period, with ongoing efforts to streamline R&D and focus on high-potential projects [10][18] - The company is actively engaging with medical directors and has secured advocacy from the American College of Rheumatology, which is expected to enhance market access and support ASP growth [14][51] Q&A Session Summary Question: What is the rationale behind the recent investments and the adjusted profitability target? - Management indicated that the investments are aimed at ensuring durable cash flow positivity and enhancing the commercial organization, which is critical for long-term growth [32][34] Question: What is the status of the myositis product development? - The company is on track to have the myositis offering ready for commercialization by 2027, following internal feasibility studies and validation of assays [36] Question: How is the ASP expected to trend in 2026? - Management expects low single-digit ASP growth relative to Q4 2025 levels, with a focus on stabilizing and gradually increasing ASP throughout the year [37][60] Question: Can you provide an update on the Northwell Health situation and its impact on volume? - Management clarified that the Northwell situation was a one-time setback, and growth initiatives have compensated for any lost volume, with positive trends observed in Q4 [39][46] Question: What is the current status of the local coverage determination for rheumatologic diseases? - The local coverage determination is still in progress, and its outcome could significantly impact the company's future product offerings and market positioning [74][75]